- Home
- PHVS vs PCRX Comparison
PHVS vs PCRX Comparison
Compare PHVS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- PCRX
- Stock Information
- Founded
- PHVS 2015
- PCRX 2006
- Country
- PHVS Switzerland
- PCRX United States
- Employees
- PHVS N/A
- PCRX N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- PCRX Health Care
- Exchange
- PHVS Nasdaq
- PCRX Nasdaq
- Market Cap
- PHVS 1.3B
- PCRX 1.2B
- IPO Year
- PHVS 2021
- PCRX 2011
- Fundamental
- Price
- PHVS $21.65
- PCRX $26.67
- Analyst Decision
- PHVS Buy
- PCRX Buy
- Analyst Count
- PHVS 6
- PCRX 6
- Target Price
- PHVS $36.67
- PCRX $30.00
- AVG Volume (30 Days)
- PHVS 118.6K
- PCRX 790.9K
- Earning Date
- PHVS 08-12-2025
- PCRX 08-05-2025
- Dividend Yield
- PHVS N/A
- PCRX N/A
- EPS Growth
- PHVS N/A
- PCRX N/A
- EPS
- PHVS N/A
- PCRX N/A
- Revenue
- PHVS N/A
- PCRX $705,848,000.00
- Revenue This Year
- PHVS N/A
- PCRX $7.36
- Revenue Next Year
- PHVS N/A
- PCRX $10.07
- P/E Ratio
- PHVS N/A
- PCRX N/A
- Revenue Growth
- PHVS N/A
- PCRX 2.25
- 52 Week Low
- PHVS $11.51
- PCRX $12.61
- 52 Week High
- PHVS $26.33
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- PHVS 47.92
- PCRX 67.86
- Support Level
- PHVS $21.56
- PCRX $25.14
- Resistance Level
- PHVS $24.52
- PCRX $27.04
- Average True Range (ATR)
- PHVS 1.32
- PCRX 0.78
- MACD
- PHVS -0.07
- PCRX 0.18
- Stochastic Oscillator
- PHVS 28.04
- PCRX 88.79
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.